Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma

Lignende værker

• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
  af: Cheng, Wen-Chien, et al.
  Udgivet: (2021)
• Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
  af: Hsia, Te‐Chun, et al.
  Udgivet: (2018)
• Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
  af: Tu, Chih-Yen, et al.
  Udgivet: (2018)
• The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation
  af: Hsia, Te-Chun, et al.
  Udgivet: (2014)
• The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
  af: Wen‐Chien Cheng, et al.
  Udgivet: (2022-05-01)